ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy

Cancer Science

Volumn 106, Issue 1, 2015, Pages 86-93

  Kim, Hee Jun ^a   Im, Seock Ah ^b,c   Keam, Bhumsuk ^b,c   Ham, Hye Seon ^c   Lee, Kyung Hun ^b,c   Kim, Tae Yong ^b,c   Kim, Yu Jung ^c,d   Oh, Do Youn ^b,c   Kim, Jee Hyun ^b,c,d   Han, Wonshik ^b,c   Jang, In Jin ^b   Kim, Tae You ^b,c   Park, In Ae ^b   Noh, Dong Young ^b,c  

^a Chung Ang University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

ABCB1 Gene; Breast cancer; C3435T; Neoadjuvant chemotherapy; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYP3A PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TAXOID;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DEATH; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC CORRELATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; GENE FREQUENCY; GENETIC ASSOCIATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP3A; DOXORUBICIN; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TAXOIDS;

EID: 84923220231     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12560     Document Type: Article

References (39)

1. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-93.
2. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-85.
3. Hortobagyi GN, Spanos W, Montague ED, Buzdar AU, Yap HY, Blumenschein GR. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys 1983; 9: 643-50.
4. Kuerer HM, Sahin AA, Hunt KK et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999; 230: 72-8.
5. Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995; 13: 537-40.
6. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000; 6: 2598-603.
7. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-31.
8. Bosch TM, Huitema AD, Doodeman VD et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12: 5786-93.
9. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006; 12: 854-9.
10. Kafka A, Sauer G, Jaeger C et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117-21.
11. Tanabe M, Ieiri I, Nagata N et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-43.
12. Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79: 570-80.
13. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998; 8: 391-401.
14. Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66: 288-94.
15. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-9.
16. Hsieh KP, Lin YY, Cheng CL et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29: 268-73.
17. Walker AH, Jaffe JM, Gunasegaram S et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998; 12: 289.
18. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
19. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-90.
20. Lan LB, Dalton JT, Schuetz EG. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 2000; 58: 863-9.
21. Han S, Kim SB, Kang SS et al. A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. Breast Cancer Res Treat 2006; 98: 57-61.
22. Keam B, Im SA, Kim HJ et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007; 7: 203.
23. Recht A, Edge SB, Solin LJ et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539-69.
24. Kong M, Hong SE. Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1- tumor and 1-3 axillary lymph nodes metastasis? Cancer Res Treat 2013; 45: 103-11.
25. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
26. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74.
27. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
28. Tang K, Ngoi SM, Gwee PC et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437-50.
29. Yamaguchi H, Hishinuma T, Endo N et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer 2006; 16: 979-85.
30. Wang LZ, Goh BC, Grigg ME, Lee SC, Khoo YM, Lee HS. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Commun Mass Spectrom 2003; 17: 1548-52.
31. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6: 71-84.
32. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-99.
33. Cizmarikova M, Wagnerova M, Schonova L et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010; 10: 62-9.
34. Kurata Y, Ieiri I, Kimura M et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72: 209-19.
35. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
36. Puisset F, Chatelut E, Dalenc F et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004; 54: 265-72.
37. Spurdle AB, Goodwin B, Hodgson E et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12: 355-66.
38. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9.
39. Kang RH, Jung SM, Kim KA et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol 2009; 29: 272-7.